✨ Free AI Report
Titan Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Titan Pharmaceuticals, Inc.
Company Research

Titan Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Titan Pharmaceuticals develops therapeutics for chronic disease treatment using its proprietary ProNeura long-term drug delivery platform. The company primarily operates through its lead product Probuphine (buprenorph...

Analyst-debate audio for Titan Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Titan Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Micro-cap turnaround play dependent on strategic merger execution and pipeline advancement; elevated execution and liquidity...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals / Drug Delivery Systems
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Titan Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Titan Pharmaceuticals, Inc. Overview

Pro stress-test →

Titan Pharmaceuticals develops therapeutics for chronic disease treatment using its proprietary ProNeura long-term drug delivery platform. The company primarily operates through its lead product Probuphine (buprenorphine implant), marketed internationally, though U.S. commercialization was discontinued in 2020 and assets were sold in 2023.

Strategic Profile

Pro stress-test →

Following discontinuation of its primary commercial product in the U.S., Titan has pivoted to exploring strategic alternatives including potential mergers and business combinations. The company maintains its proprietary ProNeura implant technology platform with early-stage pipeline candidates, though the company experienced a significant business transformation with a merger completion in October 2025.

Competitive Landscape

Pro stress-test →

Titan operates in the specialty pharmaceutical space focusing on opioid use disorder and chronic disease treatment. Primary competition comes from established opioid maintenance therapy providers and broader drug delivery platform companies. Market position is considerably weakened post-merger and asset divestiture.

Industry Context

Titan Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Drug Delivery Systems.

Key facts

Founded: 1992 · Headquarters: South San Francisco, CA, United States · Employees: N/A · Revenue: N/A · Market cap: ~$3-5M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Titan Pharmaceuticals, Inc..

  • Company completed merger with Black Titan Corporation in October 2025; original TTNP shares ceased trading on NASDAQ with Black Titan shares anticipated to begin trading
  • ProNeura platform technology remains proprietary asset with early-stage pipeline candidate TP-2021 for chronic pruritus in non-clinical development
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025Completed merger with Black Titan Corporation; TTNP shares ceased trading on Nasdaq
  • September 2023Sold Probuphine product assets following discontinuation of U.S. commercialization
  • +2 moreTrack every material event for Titan Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Titan Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Buprenorphine productsLeading buprenorphine for opioid use disorder→Long-acting opioid treatmentsOpioid addiction treatment portfolio→Drug delivery platformsTransdermal and implant delivery technologies→

Compare Titan Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Titan Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Drug Delivery Systems. See how the rest of the sector scores on the Cyborg framework.

Top companies in Specialty Pharmaceuticals by Cyborg Score

Browse Specialty Pharmaceuticals / Drug Delivery Systems research →
NEW · MCP server

Ask your AI assistant about Titan Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Titan Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Titan Pharmaceuticals, Inc. do this quarter?”
“Is Titan Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Titan Pharmaceuticals, Inc. do?+
Titan Pharmaceuticals develops therapeutics for chronic disease treatment using its proprietary ProNeura long-term drug delivery platform. The company primarily operates through its lead product Probuphine (buprenorph...
What is Titan Pharmaceuticals, Inc.'s Cyborg Score?+
Titan Pharmaceuticals, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Titan Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Buprenorphine products, Long-acting opioid treatments, Drug delivery platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Titan Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Titan Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Titan Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Catalyst Pharmaceuticals, Inc.7Achieve Life Sciences, Inc.7Assertio Holdings, Inc.7Viatris Inc.7Xeris Biopharma Holdings, Inc.6Allergy Therapeutics PLC6Eagle Pharmaceuticals Inc.6Santhera Pharmaceuticals Holding AG6Supernus Pharmaceuticals, Inc.5Amphastar Pharmaceuticals, Inc.Top companies in Specialty Pharmaceuticals by Cyborg Score